GlassScriptPhysician profile
Kevin K Wall
NPI 1285673087
$4,488.70
in general payments reported to CMS, 2019-2025
34 companies · $18.16 in 2025
The $18.16 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $892 · 2021: $1,255 · 2022: $1,344 · 2023: $42.45 · 2024: $182 · 2025: $18.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $242.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $429.33 | 2019-2024 | |
| Amgen INC. | $425.00 | 2019-2022 | |
| Abbvie INC. | $404.40 | 2019-2022 | |
| Novo Nordisk INC | $346.54 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $321.89 | 2019-2022 | |
| Lilly USA, LLC | $278.47 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $246.51 | 2019-2022 | |
| Amarin Pharma, INC. | $217.99 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $202.09 | 2019-2022 | |
| Allergan, INC. | $200.29 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.19 | 2019-2022 | |
| Glaxosmithkline, LLC. | $193.62 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Jazz Pharmaceuticals INC. | $126.08 | 2024 | |
| Sanofi-Aventis U.S. LLC | $110.13 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.62 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $99.49 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.45 | 2019-2022 | |
| Astellas Pharma US INC | $65.44 | 2019-2021 | |
| Eisai INC. | $58.50 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.72 | 2022 | |
| Merck Sharp & Dohme LLC | $47.62 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $36.89 | 2019 | |
| Radius Health, INC. | $35.33 | 2019-2022 | |
| Grifols USA, LLC | $31.77 | 2019-2021 | |
| Dexcom, INC. | $28.81 | 2021 | |
| Nevro Corp. | $23.85 | 2024 | Senza |
| Biohaven Pharmaceuticals, INC. | $23.70 | 2021 | |
| Abbott Laboratories | $19.55 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.16 | 2025 | Caplyta |
| Esperion Therapeutics, INC. | $16.23 | 2021 | |
| Shire North American Group INC | $13.25 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.67 | 2021 | |
| Corium, LLC | $12.08 | 2023 | Adlarity |
| Regeneron Healthcare Solutions, INC. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.